Photo from Jorge Cortes/X
Aug 18, 2024, 15:03
Jorge Cortes: Olutasidenib among patients with R/R AML mIDH1 previously treated with venetoclax
Jorge Cortes, Director of the Georgia Cancer Center, shared on X about recent paper by him as first author titled “Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)” published on Taylor and Francis Online.
Authors: Jorge Cortes, Brian A. Jonas, Gary Schiller, Alice Mims, Gail J. Roboz, Andrew H. Wei, Pau Montesinos, P. Brent Ferrell, Karen WL. Yee, Pierre Fenaux, Anthony Schwarer and Justin M. Watts
“Published the experience with olutasidenib among patients with R/R AML mIDH1 previously treated with venetoclax. Small series but providing useful information for a common scenario in the clinic.”
Source: Jorge Cortes/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12